This entry has been replaced by an amended Lobbying Activity Report:
1326-16733
|
Organization:
|
Eli Lilly Canada Inc.
|
|
Associated registration:
|
1913-1326-23
|
|
Lobbying Activity date:
|
2022-02-03
|
|
Arranged a meeting:
|
Yes
|
|
Posted date:
|
2022-03-11
|
| In-house lobbyists who participated in the lobbying activity: |
Dean Stewart
|
|
Senior Public Office Holders who were lobbied in this activity:
|
Clifford Lo,
Director of the Formulary
Formulary Management,
Health
|
| |
Subject Matter of the Lobbying Activity
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Health - Development, establishment, amendment or termination of any program, policy or decision, with respect to:
Policy discussions related to Patented Medicine Prices Review Board (PMPRB) and pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA) initiatives, public drug plan reimbursement and design and health system design
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
| |
|
Lobbying Activity Report replaced on:
|
2022-03-11
amended entry:
1326-16733
|
| |
|
Senior officer who filed this Lobbying Activity Report:
|
Rhonda Pacheco
|
| |
|
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
|